Published in J Clin Oncol on March 19, 2007
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care (2009) 2.10
Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys (2008) 1.95
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health (2013) 1.46
The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol (2015) 1.40
Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci (2012) 1.30
Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol (2013) 1.21
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med (2010) 1.13
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Secondary malignancies across the age spectrum. Semin Radiat Oncol (2010) 1.04
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol (2010) 0.96
Second malignancies among elderly survivors of cancer. Oncologist (2011) 0.95
Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health (2012) 0.94
Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol (2012) 0.94
Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol (2014) 0.94
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet (2007) 0.93
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol (2011) 0.93
Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys (2011) 0.92
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin Transl Gastroenterol (2016) 0.92
Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. BMC Cancer (2012) 0.89
Current knowledge and future research directions in treatment-related second primary malignancies. EJC Suppl (2014) 0.85
Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study. Ann Oncol (2012) 0.84
Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. Hematol Oncol Clin North Am (2014) 0.84
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer (2012) 0.84
Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer (2010) 0.83
Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications. Insights Imaging (2015) 0.82
Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts. Br J Cancer (2012) 0.82
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol (2011) 0.81
Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol (2010) 0.79
Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol (2016) 0.79
Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer (2012) 0.78
Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer (2014) 0.78
Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer (2017) 0.77
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica (2015) 0.77
Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: a report from the Childhood Cancer Survivor Study. Cancer (2015) 0.77
Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol (2012) 0.77
Care of the adult Hodgkin lymphoma survivor. Am J Med (2011) 0.77
Modeling the risk of secondary malignancies after radiotherapy. Genes (Basel) (2011) 0.76
Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol (2015) 0.76
Modeling age-dependent radiation-induced second cancer risks and estimation of mutation rate: an evolutionary approach. Radiat Environ Biophys (2014) 0.76
Secondary Neuroendocrine Carcinoma Following High-Dose Radiotherapy for Head and Neck Cancer: Report of Two Cases. Cureus (2016) 0.75
Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica (2014) 0.75
A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation? BMC Cancer (2016) 0.75
Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors. J Hematop (2009) 0.75
Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence. Dtsch Arztebl Int (2015) 0.75
Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study. Radiat Oncol (2014) 0.75
Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study. Int J Cancer (2017) 0.75
Triple jeopardy for Hodgkin lymphoma survivors? Blood (2014) 0.75
Breast cancer following spinal irradiation for a childhood cancer: A report from the Childhood Cancer Survivor Study. Radiother Oncol (2015) 0.75
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. Cancer (2013) 0.75
Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiat Res (2017) 0.75
Secondary cancer in a survivor of Hodgkin's lymphoma: A case report and review of the literature. Oncol Lett (2014) 0.75
Improved survival time trends in Hodgkin's lymphoma. Cancer Med (2016) 0.75
The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years? Biomed Res Int (2015) 0.75
Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History. J Clin Oncol (2017) 0.75
Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. Br J Cancer (2017) 0.75
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med (2013) 13.92
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Mobile phone use and the risk of acoustic neuroma. Epidemiology (2004) 6.04
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol (2002) 5.81
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med (2007) 4.95
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Origins and genetic legacy of Neolithic farmers and hunter-gatherers in Europe. Science (2012) 3.82
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Long-term mobile phone use and brain tumor risk. Am J Epidemiol (2005) 3.80
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst (2003) 3.67
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Nitrate in public water supplies and the risk of colon and rectum cancers. Epidemiology (2003) 3.39
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol (2008) 3.29
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst (2009) 3.17
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst (2005) 3.02
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology (2002) 3.00
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol (2011) 2.78
A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A (2006) 2.78
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer (2006) 2.73
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol (2006) 2.66
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63